Cor Therapeutics Inc. (CORR) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cor Therapeutics Inc. (CORR)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JW@KSC who wrote (191)	4/2/1998 11:22:00 AM
From: Labrador	Read Replies (1) of 712

Thursday April 2, 10:53 am Eastern Time RESEARCH ALERT - COR Therapeutics raised NEW YORK, April 2 (Reuters) - CIBC Oppenheimer analyst Matt Geller said he upgraded COR Therapeutics Inc. to strong buy from hold. -- set $30 year-end price target on the stock. -- cited news the company received a letter from the U.S. Food and Drug Administration stating that its drug Integrelin is approvable for the treatment of patients with acute coronary syndromes and for use in angioplasty. -- said Integrelin was the ''first real drug now for patients who come to the hospital with unstable angina.''

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next